Bicycle Therapeutics PLC (BCYC): Shareholders' Equity
$609.98M
As of 2025-12-31
$510.25M
As of 2026-06-30
+31.1%
3-year compound annual growth
+44.9%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $609.98M | -23.1% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $793.06M | +113.8% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $370.93M | +37.0% | 2026-03-17, Balance as of period end |
| 2022-12-31 | $270.78M | -21.8% | 2025-02-25, Balance as of period end |
| 2021-12-31 | $346.25M | +262.7% | 2024-02-20, Balance as of period end |
| 2020-12-31 | $95.46M | +2.4% | 2023-02-28, Balance as of period end |
| 2019-12-31 | $93.20M | n/m | 2022-03-01, Balance as of period end |
| 2018-12-31 | -$69.83M | n/m | 2021-03-11, Balance as of period end |
| 2017-12-31 | -$47.18M | n/a | 2020-03-10, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $609.98M | -23.1% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $206.75M | +519.8% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $722.17M | +7.5% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $966.90M | -8.4% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $36.98M | +13.5% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $99.01M | n/m |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $174.13M | -57.9% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $59.02M | +28.0% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $26.15M | +7.1% |
Compare BCYC, ASMB, VRDN, ABCL side by side · Screen every company in Pharmaceutical Preparations ↗